Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial-Reference-Cited by-同舟云学术

Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial

Published:2018-05-17 Issue:5 Volume:181 Page:628-636
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Richardson Paul G.¹^ORCID,Schlossman Robert L.²,Roy Anuja N.³,Panneerselvam Ashok³,Acharyya Suddhasatta³,Sopala Monika⁴,Lonial Sagar⁵

Affiliation:

1. Dana-Farber Cancer Institute; Boston MA USA

2. Jerome Lipper Multiple Myeloma Center; Dana-Farber Cancer Institute; Boston MA USA

3. Novartis; East Hanover NJ USA

4. Novartis Pharma AG; Basel Switzerland

5. Winship Cancer Institute; Emory University School of Medicine; Atlanta GA USA

Funder

Novartis Pharmaceuticals Corporation

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15248/fullpdf

Reference27 articles.

1. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature;Badros;Cancer,2007

2. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma;Berdeja;Haematologica,2015

3. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients;Bringhen;Blood,2010

4. Treatment trade-offs in myeloma: a survey of consecutive patients about contemporary maintenance strategies;Burnette;Cancer,2013

5. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy;Calhoun;International Journal of Gynecological Cancer,2003

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in dual-targeting inhibitors of HDAC6 for cancer treatment;European Journal of Medicinal Chemistry;2024-09

3. Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development;Blood Cancer Journal;2023-05-16

4. The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies;Journal of Cancer Survivorship;2023-01-16

5. Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study;Clinical Lymphoma Myeloma and Leukemia;2023-01